GT Biopharma Inc. (NASDAQ:GTBP) on Monday said its recently implemented artificial intelligence-based technologies are improving drug discovery productivity and pipeline development efficiency, with the company expecting additional development candidates to advance into pre-IND development in 2027.
AI Tools Drive Discovery And Engineering Efficiencies
Something went wrong.
The clinical-stage immuno-oncology company, which develops therapies based on its proprietary natural killer cell engager TriKE platform, said the new AI initiatives have enhanced its drug engineering capabilities and accelerated discovery efforts.
According to Michael Breen, executive chairman and CEO, GT Biopharma is continuing to advance its lead programs, GTB-3650 and GTB-5550, through Phase 1 studies this year while also focusing on next-generation assets that could offer shorter development timelines, improved odds of clinical success, and lower development costs.
